Amgen, Inc. (AMGN) Shares Bought by Dorsey & Whitney Trust CO LLC

Dorsey & Whitney Trust CO LLC raised its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,357 shares of the medical research company’s stock after buying an additional 51 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Amgen were worth $923,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. TrimTabs Asset Management LLC boosted its holdings in shares of Amgen by 88.9% in the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after purchasing an additional 288 shares during the period. American Beacon Advisors Inc. purchased a new position in shares of Amgen in the 1st quarter worth approximately $106,000. Jackson Grant Investment Advisers Inc. boosted its holdings in shares of Amgen by 0.8% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5 shares during the period. Omnia Family Wealth LLC boosted its holdings in shares of Amgen by 25.3% in the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after purchasing an additional 147 shares during the period. Finally, Grove Bank & Trust boosted its holdings in shares of Amgen by 87.4% in the 2nd quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock worth $126,000 after purchasing an additional 341 shares during the period. Institutional investors and hedge funds own 78.38% of the company’s stock.

Shares of Amgen, Inc. (NASDAQ AMGN) opened at $178.67 on Wednesday. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05. The firm has a market capitalization of $130,080.00, a price-to-earnings ratio of 14.09, a price-to-earnings-growth ratio of 2.57 and a beta of 1.36. Amgen, Inc. has a 1 year low of $138.83 and a 1 year high of $191.10.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. Amgen had a return on equity of 25.35% and a net margin of 35.01%. Amgen’s revenue was down .7% on a year-over-year basis. During the same period in the previous year, the company posted $3.02 EPS. equities research analysts predict that Amgen, Inc. will post 12.66 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Friday, November 17th will be given a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a yield of 2.57%. The ex-dividend date is Thursday, November 16th. Amgen’s dividend payout ratio (DPR) is presently 41.55%.

Amgen announced that its Board of Directors has authorized a share buyback plan on Wednesday, October 25th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Shares buyback plans are often an indication that the company’s leadership believes its stock is undervalued.

A number of equities analysts have recently commented on the company. Cann reiterated a “buy” rating and issued a $205.00 target price on shares of Amgen in a report on Thursday, November 30th. Oppenheimer reiterated a “buy” rating and issued a $205.00 target price on shares of Amgen in a report on Thursday, November 30th. BMO Capital Markets reiterated a “hold” rating and issued a $199.00 target price on shares of Amgen in a report on Monday, September 25th. BidaskClub upgraded Amgen from a “strong sell” rating to a “sell” rating in a report on Saturday. Finally, Credit Suisse Group reissued a “neutral” rating and set a $186.00 price target (up from $177.00) on shares of Amgen in a research note on Friday, September 29th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $190.22.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Monday, October 9th. The stock was sold at an average price of $185.95, for a total transaction of $283,573.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 7,050 shares of company stock valued at $1,239,673. 0.19% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.com-unik.info/2017/12/06/amgen-inc-amgn-shares-bought-by-dorsey-whitney-trust-co-llc.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

What are top analysts saying about Amgen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amgen Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit